- Conditions
- Diabetic Macular Edema, Retina Vein Occlusion
- Interventions
- GB-102
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Savannah, Georgia • Louisville, Kentucky + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinal Vein Occlusion
- Interventions
- Ranibizumab (Lucentis )
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Interventions
- nicotinic acid
- Drug
- Lead sponsor
- Palo Alto Medical Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- FYB203 2 mg (0.05 mL of 40 mg/mL)
- Drug
- Lead sponsor
- Formycon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Campbell, California • Long Beach, California • Redlands, California + 1 more
- Conditions
- Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
- Interventions
- Episcleral Celecoxib
- Drug
- Lead sponsor
- Targeted Therapy Technologies, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Macular Edema With Central Retinal Vein Occlusions
- Interventions
- Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Bakersfield, California • Santa Barbara, California • Santa Maria, California
- Conditions
- Macular Edema, Cystoid, Retinal Vein Occlusion
- Interventions
- Standard Care, intravitreal triamcinolone injection
- Other · Drug
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
- Interventions
- Refresh Plus Preservative-free Lubricant Eye Drops
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Macular Edema
- Interventions
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Device · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Interventions
- LKA651, Sham Comparator
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema
- Interventions
- FYB201 0.5 mg (0.05 mL of 10 mg/mL)
- Drug
- Lead sponsor
- Formycon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Campbell, California • Long Beach, California • Hagerstown, Maryland + 1 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Drug
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- suprachoroidal CLS-TA, suprachoroidal sham, Lucentis or Avastin
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more
- Conditions
- Macular Edema, Macular Degeneration
- Interventions
- RHMS-RTM, SD-OCT
- Device · Diagnostic Test
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- VEGF Trap-Eye 2.0mg, Sham
- Biological · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more
- Conditions
- Macular Edema Secondary to Retinal Vein Occlusion
- Interventions
- Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
- Drug · Diagnostic Test
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 53
- States / cities
- Fullerton, California • Long Beach, California • Mountain View, California + 48 more
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- aflibercept, bevacizumab
- Drug
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- 4 mg CLS-TA, Sham, IVT aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
- Conditions
- Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
- Interventions
- Episcleral Dexamethasone
- Drug
- Lead sponsor
- Targeted Therapy Technologies, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
- Procedure · Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Clearwater, Florida